OPKO Health Q4 Earnings Call Highlights

Core Insights - OPKO Health is undergoing a transformative phase following the divestiture of its oncology division, allowing it to concentrate on its core clinical laboratory business and improve operational efficiency [2][6][19] Financial Performance - OPKO reported Q4 2025 consolidated revenue of $148.5 million, down from $183.6 million in Q4 2024, with an operating loss of $38.3 million compared to a loss of $33.1 million in the prior year [4][18] - The company ended 2025 with $369 million in cash and repurchased 34.6 million shares for approximately $47 million [4][13] - For full-year 2026, OPKO anticipates revenue between $530 million and $560 million, with total costs expected to be between $725 million and $750 million, primarily due to increased R&D spending [4][19] Operational Changes - BioReference reduced its workforce by approximately 29% to about 1,400 employees, which is part of broader operational efficiency initiatives [1][6] - The testing volume at BioReference grew slightly in Q4 2025, excluding divested oncology assets, and is expected to improve margins and cash flow in 2026 [1][6] Product Development and Pipeline - ModeX is now a clinical-stage platform with multiple programs, including a partnered EBV vaccine with Merck, which has enrolled over 200 subjects in a Phase 1 trial [5][8] - OPKO's lead immuno-oncology program, MDX-2001, has dosed over 25 patients, showing early signs of efficacy [14] - The company is also advancing its in vivo CAR-T platform, with plans to enter clinical trials by late 2026 or early 2027 [12] Strategic Collaborations - OPKO's collaboration with Regeneron combines resources for multiple programs in metabolism, oncology, and immunology, with potential milestones exceeding $1 billion [9] - The company received $28.5 million in non-dilutive funding from BARDA for its COVID-19 and influenza programs in 2025 [11]